News

NEW YORK, NY, April 21, 2026 – Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine.

NEW YORK, NY, March 23, 2026 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma.

NEW YORK, NY, March 17, 2026 – Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026.

NEW YORK, NY, March 2, 2026 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.

NEW YORK, NY, September 29, 2025 – Royalty Pharma plc today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.

NEW YORK, NY, September 19, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.

NEW YORK, NY, September 2, 2025 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”)...

NEW YORK, NY, August 13, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.

NEW YORK, NY, July 17, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately.

NEW YORK, NY, April 8, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.